7-chloro-benzothiazol-6-ylamine | 70202-00-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 7-chloro-benzothiazol-6-ylamine
• 英文别名: 7-Chloro-6-aminobenzothiazole；7-chloro-1,3-benzothiazol-6-amine
• CAS: 70202-00-5
• 化学式: C₇H₅ClN₂S
• 分子量: 184.649
• InChiKey: VZJOLXNLUGOOQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  7-chloro-benzothiazol-6-ylamine 在 potassium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.17h， 生成 4-chloro-5-ethyl-8-oxo-5,8-dihydro-thiazolo[4,5-g]quinoline-7-carboxylic acid ethyl ester
  参考文献：
  名称：

  Synthesis of antimicrobial agents. I. Synthesis and antimicrobial activities of thiazoloquinoline derivatives.

  摘要：

  通过以下两种方法制备了一系列取代的噻唑并[4，5-g]-、[5，4-g]-、[4，5-h]-和[5，4-h]喹啉羧酸，目的是提供新的抗菌药物。其中一种合成方法是通过氨基苯并噻唑与乙氧基亚甲基丙二酸二乙酯缩合、Gould-Jacobs 反应、N-烷基化和水解等连续步骤进行的。另一种是正交氨基巯基喹啉的噻唑环化反应。这项工作中制备的这些化合物在体外进行了抗菌活性评估。9-氯-8-乙基-5, 8-二氢-5-氧代噻唑并-[4, 5-g] 喹啉-6-羧酸（28b）的活性最高。

  DOI：

  10.1248/cpb.27.1
• 作为产物：
  描述：

  2,7-Dichlor-6-nitro-benzthiazol 生成 7-chloro-benzothiazol-6-ylamine
  参考文献：
  名称：

  SUZUKI NORIO; TANAKA YOSHIAKI; DOHMORI RENZO, CHEM. AND PHARM. BULL., 1979, 27, NO 1, 1-11

  摘要：

  DOI：

文献信息

• [EN] HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2<br/>[FR] COMPOSÉS HÉTÉROBICYCLIQUES POUR INHIBER L'ACTIVITÉ DE SHP2
  申请人：TAIHO PHARMACEUTICAL CO LTD

  公开号：WO2020022323A1

  公开（公告）日：2020-01-30

  A compound of formula (I):wherein Ring A, Q, R1,R2, R3, R4, R5, R6, R7, R8, R9, R10, R11,X, a,b, c and d are as defined in the specification.

  其中环A，Q，R1，R2，R3，R4，R5，R6，R7，R8，R9，R10，R11，X，a，b，c和d的化合物的化学式（I）：在规范中定义。
• 5- and 6-(2-imidazolin-2-ylamino) and
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05677321A1

  公开（公告）日：1997-10-14

  This invention is directed to indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

  这项发明涉及选择性作用于克隆人类α2受体的吲哚和苯并噻唑化合物。该发明还涉及这些化合物在任何需要使用α2激动剂的适应症中的用途。具体包括用作镇痛剂、镇静剂和麻醉剂。此外，该发明包括使用这些化合物降低眼内压、治疗老花眼、偏头痛、高血压、酒精戒断、药物成瘾、类风湿性关节炎、缺血性疼痛、痉挛、腹泻、鼻塞、尿失禁，以及用作认知增强剂和眼部血管收缩剂。该发明还提供一种包含上述定义化合物的治疗有效量和药用可接受载体的药物组合物。
• Novel indole and benzothiazole derivatives
  申请人：SYNAPTIC PHARMACEUTICAL CORPORATION

  公开号：US20020049239A1

  公开（公告）日：2002-04-25

  This invention is directed to novel indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

  本发明涉及新型的吲哚和苯并噻唑化合物，这些化合物对克隆的人类α2受体具有选择性。本发明还涉及这些化合物在任何需要使用α2激动剂的适应症中的用途。具体包括用作镇痛剂、镇静剂和麻醉剂。此外，本发明还包括使用这些化合物降低眼内压、治疗老视、偏头痛、高血压、酒精戒断、药物成瘾、类风湿性关节炎、缺血性疼痛、痉挛、腹泻、鼻塞、尿失禁以及用作认知增强剂和眼部血管收缩剂。本发明还提供了一种药物组合物，其中包括上述定义的化合物的治疗有效量和药学可接受的载体。
• Benzimidazoles and benzothiazoles and uses thereof
  申请人：SYNAPTIC PHARMACEUTICAL CORPORATION

  公开号：US20030105147A1

  公开（公告）日：2003-06-05

  This invention is directed to novel indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

  本发明涉及一种新型的吲哚和苯并噻唑化合物，其对克隆人类α2受体具有选择性。本发明还涉及使用这些化合物的用途，适用于任何需要使用α2激动剂的情况。具体来说，这包括用作镇痛剂、镇静剂和麻醉剂。此外，本发明还包括使用这些化合物降低眼压、老视、治疗偏头痛、高血压、酒精戒断、药物成瘾、类风湿性关节炎、缺血性疼痛、痉挛、腹泻、鼻塞、尿失禁以及用作认知增强剂和眼部血管收缩剂。本发明还提供了一种包含上述定义化合物的治疗有效量和药学上可接受的载体的药物组合物。
• Substituted indoles and uses thereof
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US06040451A1

  公开（公告）日：2000-03-21

  This invention is directed to novel indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

  本发明涉及一种新型的吲哚和苯并噻唑化合物，其对克隆的人类α2受体具有选择性。本发明还涉及这些化合物在任何需要使用α2激动剂的适应症中的用途。具体包括用作镇痛剂、镇静剂和麻醉剂。此外，本发明还包括使用这些化合物降低眼压、治疗老视眼、偏头痛、高血压、酒精戒断、药物成瘾、类风湿性关节炎、缺血性疼痛、痉挛、腹泻、鼻塞和尿失禁，以及用作认知增强剂和眼部血管收缩剂。本发明还提供一种药物组合物，其中包括上述定义的化合物的治疗有效量和药学上可接受的载体。